From:	ehud barak <ehbarak1@gmail.com>
To:	Nikolic Boris <Boris.Nikolic@bgc3.com>
CC:	
Date:	Sun, 8/11/2013 9:20:48 PM
Subject:	Fwd: Parasight Ltd.

Dear Boris
Attached as promised pl find Parasight presentation.
Pl send me your initial response and we'll consider how to continue with them.
Best
Ehud Barak

Sent from my iPhone

Begin forwarded message:

From: Doron <doronco@netvision.net.il>
Date: August 11, 2013, 18:52:33 GMT+03:00
To: Ehud BARAK <ehbarak1@gmail.com>
Subject: Fwd: Parasight Ltd.

Dear Dr. Nikolic,

Parasight Ltd was founded two years ago in Israel in order to develop a platform technology for blood analysis and parasite detection. During this time, Parasight has focused on developing an innovative device for the accurate, rapid and inexpensive diagnosis of Malaria, suitable for POC and labs in Malaria-endemic countries as well as blood banks everywhere. The device is based on the latest technologies in the field of machine-vision together with breakthrough advances in sample preparation and staining.

Following Mr. Barak's communication with you, we are proud to present the official report describing the results of our first clinical trial, which was conducted recently in India by the National Institute of Malaria Research. As the report indicates, our clinical accuracy is on par with PCR, but with ease of use and cost commensurate with RDTs. Additionally, I am attaching an executive summary describing the company. Our goal is to introduce Parasight's technology to the Gates Foundation in hopes of advancing the project and reaching the target population.

As it happens, our co-founder and Chairman of the Scientific Advisory Board, Dr. Daniel Levner, is a Senior Staff Scientist at Harvard Medical School, so perhaps the best way to present our technology would be through a meeting. Please let me know what would be best for you.

Thanks,

Yossi Pollak
Chief Executive Officer
Parasight LTD I Jerusalem Technology Park, Israel
T +972 2 6737370 I F +972 2 6737371 I M +972 54 4688857
Yossi Pollak

PARASIGHT EXECUTIVE SUMMARY_V1.8.pdf

CL-IN002__Report_signed.pdf